Polyglutamine expansion diseases: More than simple repeats
- PMID: 28928079
- DOI: 10.1016/j.jsb.2017.09.006
Polyglutamine expansion diseases: More than simple repeats
Abstract
Polyglutamine (polyQ) repeat-containing proteins are widespread in the human proteome but only nine of them are associated with highly incapacitating neurodegenerative disorders. The genetic expansion of the polyQ tract in disease-related proteins triggers a series of events resulting in neurodegeneration. The polyQ tract plays the leading role in the aggregation mechanism, but other elements modulate the aggregation propensity in the context of the full-length proteins, as implied by variations in the length of the polyQ tract required to trigger the onset of a given polyQ disease. Intrinsic features such as the presence of aggregation-prone regions (APRs) outside the polyQ segments and polyQ-flanking sequences, which synergistically participate in the aggregation process, are emerging for several disease-related proteins. The inherent polymorphic structure of polyQ stretches places the polyQ proteins in a central position in protein-protein interaction networks, where interacting partners may additionally shield APRs or reshape the aggregation course. Expansion of the polyQ tract perturbs the cellular homeostasis and contributes to neuronal failure by modulating protein-protein interactions and enhancing toxic oligomerization. Post-translational modifications further regulate self-assembly either by directly altering the intrinsic aggregation propensity of polyQ proteins, by modulating their interaction with different macromolecules or by modifying their withdrawal by the cell quality control machinery. Here we review the recent data on the multifaceted aggregation pathways of disease-related polyQ proteins, focusing on ataxin-3, the protein mutated in Machado-Joseph disease. Further mechanistic understanding of this network of events is crucial for the development of effective therapies for polyQ diseases.
Keywords: Aggregation modulation; Ataxin-3; Molecular partner; Neurodegenerative disease; Polyglutamine protein; Post-translational modification.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Polyglutamine-Independent Features in Ataxin-3 Aggregation and Pathogenesis of Machado-Joseph Disease.Adv Exp Med Biol. 2018;1049:275-288. doi: 10.1007/978-3-319-71779-1_14. Adv Exp Med Biol. 2018. PMID: 29427109 Review.
-
Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Prog Neurobiol. 2011. PMID: 21740957 Review.
-
Polyglutamine tracts regulate beclin 1-dependent autophagy.Nature. 2017 May 4;545(7652):108-111. doi: 10.1038/nature22078. Epub 2017 Apr 26. Nature. 2017. PMID: 28445460 Free PMC article.
-
PolyQ-expanded proteins impair cellular proteostasis of ataxin-3 through sequestering the co-chaperone HSJ1 into aggregates.Sci Rep. 2021 Apr 9;11(1):7815. doi: 10.1038/s41598-021-87382-w. Sci Rep. 2021. PMID: 33837238 Free PMC article.
-
A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.Cell Death Dis. 2021 Feb 2;12(2):136. doi: 10.1038/s41419-021-03444-x. Cell Death Dis. 2021. PMID: 33542212 Free PMC article.
Cited by
-
PolyQ length co-evolution in neural proteins.NAR Genom Bioinform. 2021 May 14;3(2):lqab032. doi: 10.1093/nargab/lqab032. eCollection 2021 Jun. NAR Genom Bioinform. 2021. PMID: 34017944 Free PMC article.
-
Spinocerebellar Ataxia Type 3 Pathophysiology-Implications for Translational Research and Clinical Studies.Int J Mol Sci. 2024 Apr 3;25(7):3984. doi: 10.3390/ijms25073984. Int J Mol Sci. 2024. PMID: 38612794 Free PMC article. Review.
-
Proteasome Activation to Combat Proteotoxicity.Molecules. 2019 Aug 5;24(15):2841. doi: 10.3390/molecules24152841. Molecules. 2019. PMID: 31387243 Free PMC article. Review.
-
EPSIN1 Modulates the Plasma Membrane Abundance of FLAGELLIN SENSING2 for Effective Immune Responses.Plant Physiol. 2020 Apr;182(4):1762-1775. doi: 10.1104/pp.19.01172. Epub 2020 Feb 24. Plant Physiol. 2020. PMID: 32094305 Free PMC article.
-
On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3.J Integr Bioinform. 2023 Feb 28;20(2):20220056. doi: 10.1515/jib-2022-0056. eCollection 2023 Jun 1. J Integr Bioinform. 2023. PMID: 36848492 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
